45 results on '"Dell’Agnello, Grazia"'
Search Results
2. Correction: Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
3. Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
4. Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea
5. Correction to: Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea
6. Treatment pattern and health care resource utilization for Taiwanese patients with migraine: a population-based study
7. Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
8. Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
9. Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process
10. Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
11. sj-pdf-2-cep-10.1177_03331024221110102 - Supplemental material for Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process
12. sj-pdf-1-cep-10.1177_03331024221110102 - Supplemental material for Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process
13. Prevalence Rates of Primary Headache Disorders and Evaluation and Treatment Patterns Among Korean Neurologists
14. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: Effects of pramipexole and pergolide on working memory
15. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study
16. Additional file 1 of Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea
17. Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions
18. BDNF Level in the Rat Prefrontal Cortex Increases Following Chronic but Not Acute Treatment with Duloxetine, a Dual Acting Inhibitor of Noradrenaline and Serotonin Re-uptake
19. Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine
20. Impaired attention modulation of the blink reflex R3 component in Parkinson's disease: a non-task warning paradigm study
21. Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer’s disease diagnosis: a pilot study in England
22. [P2-307]: INTERMEDIATE CHANGES IN COGNITION PREDICT LONG TERM OUTCOMES IN MILD ALZHEIMER's DISEASE DEMENTIA
23. Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes
24. Effectiveness of Florbetapir PET Imaging in Changing Patient Management
25. Describing the Sequence of Cognitive Decline in Alzheimer’s Disease Patients: Results from an Observational Study
26. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
27. Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England.
28. DT-02-03: A randomized, controlled, multicenter, international study of the impact of florbetapir (18 F) PET amyloid imaging on patient management and outcome
29. INTERMEDIATE CHANGES IN COGNITION PREDICT LONG TERM OUTCOMES IN MILD ALZHEIMER’S DISEASE DEMENTIA
30. P4‐311: IS FLORBETAPIR‐PET OCCIPITAL SUVR A LATE BIOMARKER IN MILD OR MODERATE AD DEMENTIA AS COMPARED TO HIPPOCAMPAL VOLUME?
31. P4-136: DOES HIPPOCAMPAL VOLUME PREDICT POSITIVE AMYLOID STATUS ON FLORBETAPIR-PET IN HEALTHY CONTROLS AND PRODROMAL STAGES OF ALZHEIMER'S DISEASE?
32. Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study
33. Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges.
34. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease
35. Adrenocorticotropic hormone and cortisol plasma levels directly correlate with childhood neglect and depression measures in addicted patients
36. Effects of an Educational Intervention on Weight Gain in Patients Treated With Antipsychotics
37. Cerebral Perfusional Effects of Cholinesterase Inhibitors in Alzheimer Disease
38. Dopaminergic Modulation of Visual-Spatial Working Memory in Parkinson’s Disease
39. Treatment of Patients With Tardive Dystonia With Olanzapine
40. SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study
41. A randomized, controlled, multicenter, international study of the impact of florbetapir (18F) PET amyloid imaging on patient management and outcome.
42. <atl>Impaired attention modulation of the blink reflex R3 component in Parkinson's disease: a non-task warning paradigm study
43. Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.
44. Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.
45. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.